PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses

SIMPLE SUMMARY: Small-cell lung cancer carries a dismal prognosis with few long-term treatment options. The enzyme poly-(ADP)-ribose polymerase (PARP), which functions to repair DNA breaks, has emerged as a promising therapeutic target, with modest response rates in early clinical trials prompting i...

Descripción completa

Detalles Bibliográficos
Autores principales: Knelson, Erik H., Patel, Shetal A., Sands, Jacob M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916546/
https://www.ncbi.nlm.nih.gov/pubmed/33578789
http://dx.doi.org/10.3390/cancers13040727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916546/
https://www.ncbi.nlm.nih.gov/pubmed/33578789
http://dx.doi.org/10.3390/cancers13040727

Ejemplares similares